Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Holding RIGL?
Track your performance easily
RIGL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.27 - $17.29
Previous Close$14.16
Volume101.87K
Average Volume (3M)136.57K
Market Cap
$249.14M
Enterprise Value$260.37M
Total Cash (Recent Filing)$49.10M
Total Debt (Recent Filing)$60.33M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 05, 2024EPS Estimate
$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding17,594,977
10 Day Avg. Volume93,805
30 Day Avg. Volume136,570
Standard Deviation0.24
R-Squared0.04
Alpha0.00892
Financial Highlights & Ratios
Price to Book (P/B)-8.33
Price to Sales (P/S)1.91
Price to Cash Flow (P/CF)206.30
P/FCF Ratio29.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.00
Enterprise Value/Gross Profit2.37
Enterprise Value/Ebitda-182.85
Forecast
1Y Price Target
$37.00Price Target Upside161.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Rigel News
PremiumCompany Announcements
Dr. Brian Kotzin Resigns from Rigel Pharmaceuticals’ Board
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal revenue came in at $36.84 million, surpassing both the analyst's estimate of $29.78 million and the consensus of $33.42 million.
Partnership And ExpansionRigel and Kissei expand partnership with addition of Rezlidhia.
Strategic CollaborationA strategic alliance with MD Anderson was announced for olutasidenib development in additional heme-onc indications.
Bears Say
Clinical Trial ConcernsFatal infections were reported in 5 patients in the Gavreto group, with none reported in the standard of care group.
Drug SafetyAn ad hoc analysis revealed a higher rate of severe and fatal infections in the Gavreto group compared to the standard of care group.
Financial RiskFactors that could impede reaching the price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.
---
Ownership Overview
20.20% Insiders
23.28% Mutual Funds
2.51% Other Institutional Investors
38.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.27 and its highest was $17.29 in the past 12 months.
What is Rigel’s market cap?
Currently, no data Available
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Nov 05, 2024 which is tomorrow.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Aug 06, 2024. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.232.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is $0.06.
How many shares outstanding does Rigel have?
Rigel has 17,594,976 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went up 5.788%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Graham Capital Management, L.P.. It holds Rigel’s shares valued at N/A.
---
Rigel Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (161.30% Upside)
$37.00 (161.30% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.67%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q2 2024
0:00 / 0:00
---
RIGL Stock 12 Month Forecast
Average Price Target
$37.00
▲(161.30% Upside)
Technical Analysis
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+23.79%
reiterated a buy rating 10 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +23.79% per trade.
---